



Docket No.: PF466P1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Moore et al.

Application No.: 09/376,430

Confirmation No.:

Filed: August 18, 1999

Art Unit: 1646

For: Cytokine Receptor Common Gamma Chain
Like

Examiner: E. O'Hara

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AI-AP listed on the attached Form PTO/SB/08A. A copy of reference AL is enclosed.

Copies of references AI-AK, and AM-AP were submitted by Applicants or cited by the Examiner in connection with copending U. S. Patent Application Serial No. 09/263,626, filed March 5, 1999. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to U. S. Patent Application Serial No. 09/263,626 for copies of references AI-AK, and AM-AP.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR §§ 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed references are not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants

do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed reference(s) and that the reference(s) be made of record in the file history of the application.


Pursuant to 37 C.F.R. § 1.97(c)(2), the Patent Office will consider this Information Disclosure Statement if filed before the mailing date of a final Office Action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in this application and accompanied by the fee set forth in § 1.17(p). Accordingly, the required fee of \$180.00 is transmitted herewith with the concurrently filed Fee Transmittal, with the appropriate fee(s).

If any additional fees are deemed necessary, the Patent & Trademark Office is authorized to charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

Dated: August 15, 2003

Respectfully submitted,

By


Janet M. Martineau

Registration No.: 46,903

HUMAN GENOME SCIENCES, INC.

9410 Key West Avenue

Rockville, Maryland 20850

(301) 315-2723



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/376,430-Conf. #6501
				Filing Date	August 18, 1999
				First Named Inventor	Paul A. Moore
				Art Unit	1646
				Examiner Name	E. O'hara
Sheet	1	of	1	Attorney Docket Number	PF466P1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	AI	WO-02/00724-A2	01-03-2002	Amgen, Inc.		
	AJ	WO-02/00723-A2	01-03-2002	Whitehead Institute of Biomedical Research		
	AK	WO-03/029423-A2	04-24-2003	Curagen Corporation		
	AL	WO-02/068646-A2 ✓	09-06-2002	Schering Corporation		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AM	BLAGOEV et al., "Cloning of rat thymic stromal lymphopoietin receptor (TSLPR) and characterization of genomic structure of murine Tslpr gene," Gene 284(1-2):161-168 (2002)	
	AN	RECHE et al., "Human thymic stromal lymphopoietin preferentially stimulates myeloid cells," J Immunology 167:336-343 (2001)	
	AO	TONOZUKA et al., "Molecular cloning of a human novel type I cytokine receptor related to $\delta 1$ /TSLPR," Cytogenet Cell Genet 93:23-25 (2001)	
	AP	ZHANG et al., "Identification of a novel type I cytokine receptor CRL2 preferentially expressed by human dendritic cells and activated monocytes," Biochem and Biophys Res Commun. 281:878-883 (2001)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--